Shattuck Labs, Inc. (STTK) investor relations documents from the company's IR site: 22 presentations, 12 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.
Presentation: Shattuck Labs' DR3 blocking antibody SL-325 is entering Phase 2b for Crohn's disease in Q3'26, with $208.3M cash runway to 2029.
STTK overview · STTK earnings · STTK financials · STTK KPIs · STTK ownership · STTK peers · STTK filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.